Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Fennec Pharmaceuticals Inc.

NASDAQ: FENC · Life Sciences · 4 alerts · CIK 1211583

Share price
$12.76Close, Nov 16
Market cap
$450M
Shares outstanding
35.31MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Fennec Pharmaceuticals Inc. filings on SEC EDGAR ↗

4:09 PM ET Form 4
Insider Selling

Fennec Pharmaceuticals Director Marco Maria Brughera Sells $240K of Stock

Marco Maria Brughera, Director, sold 20,000 shares of Fennec Pharmaceuticals Inc. at $12.00 a share, worth $240K in total on Nov 13, 2026. Shares held after the trade: 0 (-100.0%).

Value
$240K
Shares
20,000
Price
$12.00
Role
Director
Holding change
-100.0%
Trade date
Nov 13, 2026
4:07 PM ET 10-Q
Financial Results

Fennec Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $4.64M

Fennec Pharmaceuticals reported a significant increase in total revenue to $19.6 million for Q3 2026, driven by PEDMARK product sales. The company achieved net income of $4.6 million compared to a net loss in the prior year, supported by a decrease in G&A expenses and improved operating margins. Cash reserves stood at $48.7 million, which management expects will be sufficient to fund operations based on the current plan.

Key figure
Net income $4.64M
4:03 PM ET 8-K
Clinical Trial Data

Fennec Pharmaceuticals Clinical Trial Data

Fennec Pharmaceuticals announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK in Japan for pediatric and AYA patients. The study met its primary endpoint, showing hearing loss in only 24.0% of patients compared to a historical benchmark of 56.4%, while demonstrating no interference with cisplatin antitumor activity.

4:05 PM ET Form 4
Insider Selling

Fennec Pharmaceuticals Director Marco Maria Brughera Sells $160K of Stock

Marco Maria Brughera, Director, sold 15,545 shares of Fennec Pharmaceuticals Inc. at $10.29 a share, worth $160K in total on Sep 15, 2026. Shares held after the trade: 0 (-100.0%).

Value
$160K
Shares
15,545
Price
$10.29
Role
Director
Holding change
-100.0%
Trade date
Sep 15, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.